3 results
Primary Objective:To compare invasive disease-free survival (iDFS) for the combination of at least 5 years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed…
The primary objective of this trial is to study the effect of the moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib, measured as AUC0-24h, Cmax and Cmin.The secondary objective of this trial is to compare the incidence…
The objectives of this exploratory study are: * To evaluate the safety and local tolerability of the new flurbiprofen 8.75 mg spray. * To compare the pharmacokinetic profile of the new flurbiprofen 8.75 mg spray to marketed flurbiprofen 8.75 mg…